Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Human Papillomavirus, Vaccines and Women's Health
share announcement

Human Papillomavirus, Vaccines and Women's Health

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 8747

Special Issue Editor

Dr. Marco Petrillo

E-Mail Website
Guest Editor
Gynecologic and Obstetric Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Interests: ovarian cancer; biochemistry; genetics and molecular biology; medicine; pharmacology, toxicology and pharmaceutics; immunology and microbiology

Special Issue Information

Dear Colleagues,

In past decades, the results of a long research journey led to the introduction of HPV vaccination for the prevention of cervical dysplasia into routine clinical practice. This scientific achievement represents a cornerstone in medical history, since for the first time we have a reliable and effective primary prevention strategy able to reduce the incidence of a highly lethal malignancy: cervical cancer. Furthermore, HPV vaccination has progressively emerged as a potentially useful preventive strategy not only for uterine malignancies and vulvar condylomas, but also for anal carcinoma and head and neck cancer which may be sustained by HPV infection. As a further advancement, compelling evidences seem to suggest that HPV vaccination may be useful as a secondary preventive strategy in patients receiving surgery for cervical dysplasia, reducing the risk of recurrence. For these reasons, HPV vaccination is progressively emerging as a safe and useful tool to preserve overall women’s health.

On the other hand, several questions remain to be addressed by the scientific community. First of all, despite the relevant benefits for women’s health, the diffusion of HPV vaccination among young teenagers remain unsatisfying, particularly in low-income areas. Furthermore, from a biological point of view, the cross protection ensured by the available vaccines against the plethora of HPV serotypes remains to be clarified; moreover, little and contrasting data have been provided regarding the potential mechanisms of viral immunological escape. Finally, from a clinical point of view, the scientific community should start to look at HPV vaccination not only as a gynecological issue, but as a general health strategy involving several fields including oncological prevention for head & neck, lung, and proctological malignancies, thus focusing more efforts on the potential relevant overall benefits of HPV vaccination also in the male population.

Following this intriguing scenario, the main objective of this Special Issue is to provide novel interesting insights regarding HPV vaccination and its potential implications for women’s health of HPV vaccination to the scientific community, moving from primary and secondary prevention of cervical dysplasia and vulvar/anal condylomas to other non-gynecological issues including proctological diseases, head & neck and lung malignancies, as well as HPV-related couple fertility problems. Furthermore, we especially welcome original research papers and review articles providing high-quality rigorous novel insights regarding biological issues related to HPV vaccination (cross-protection, mechanisms of immunological escape, etc.), as well as epidemiological and community studies investigating the issues of HPV vaccination initiatives all over the world. 

With the hope of an enthusiastic participation of the scientific community, we launch here the Vaccines Special Issue entitled: “Human Papillomavirus, Vaccines and Women's Health.”

Dr. Marco Petrillo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HPV vaccination
  • condylomas
  • cervical cancer
  • head and neck cancer
  • anal cancer
  • lung cancer
  • immunological escape

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2229 KiB  
Article
Prevalence of HPV Infection and p16INK4a Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma
by Roberto Gallus, Tarik Gheit, Dana Holzinger, Marco Petrillo, Davide Rizzo, Gianluigi Petrone, Francesco Miccichè, Gian Carlo Mattiucci, Damiano Arciuolo, Giampiero Capobianco, Giovanni Delogu, Vincenzo Valentini, Massimo Tommasino and Francesco Bussu
Vaccines 2022, 10(2), 204; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10020204 - 27 Jan 2022
Cited by 6 | Viewed by 2289
Abstract
Background: The mucosal high-risk (HR) human papillomavirus (HPV) is associated with oropharyngeal carcinogenesis. Aims of this study were to evaluate the prevalence of HR-HPV infection in laryngeal squamous cell carcinoma (LSCC) from different subsites, and the clinico-biological meaning of p16 overexpression. Methods: Ninety-seven [...] Read more.
Background: The mucosal high-risk (HR) human papillomavirus (HPV) is associated with oropharyngeal carcinogenesis. Aims of this study were to evaluate the prevalence of HR-HPV infection in laryngeal squamous cell carcinoma (LSCC) from different subsites, and the clinico-biological meaning of p16 overexpression. Methods: Ninety-seven LSCCs submitted to primary surgery (n = 75) or to post-irradiation salvage laryngectomy (n = 22) were evaluated for HR-HPV DNA and RNA using Luminex-based assays. p16 immunohistochemistry was performed. Results: HR-HPV DNA from HPV16 was detected in seven cases (8.75%), without significant differences between supraglottic and glottic lesions. HPV RNA was never detected. p16 overexpression correlated with HR-HPV DNA, but the kappa agreement score was poor. HPV DNA showed no impact on prognosis. p16 overexpression was associated with a better survival (OS, RFS) in primarily operated cases, while an inverse association with OS was observed in the salvage surgery group. Conclusions: HR-HPV infection appears to have a marginal role in LSCC independent of the anatomical subsite. p16 expression is deregulated in LSCC independent of HPV but displays a prognostic role in patients submitted to primary surgery. The negative predictive role of p16 overexpression in patients undergoing salvage surgery deserves more investigations for validation and elucidation of its clinical relevance. Full article
(This article belongs to the Special Issue Human Papillomavirus, Vaccines and Women's Health)
►▼ Show Figures

Figure 1

15 pages, 1607 KiB  
Article
Attitude towards HPV Vaccination and the Intention to Get Vaccinated among Female University Students in Health Schools in Jordan
by Malik Sallam, Kholoud Al-Mahzoum, Huda Eid, Areej M. Assaf, Maram Abdaljaleel, Mousa Al-Abbadi and Azmi Mahafzah
Vaccines 2021, 9(12), 1432; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9121432 - 03 Dec 2021
Cited by 28 | Viewed by 5828
Abstract
Cervical cancer is a leading cause of morbidity and mortality in women worldwide. The availability of prophylactic vaccines for high-risk types of human papillomavirus (HPV) infection represents an important advancement in the prevention of cervical cancer. In Jordan, the availability of the HPV [...] Read more.
Cervical cancer is a leading cause of morbidity and mortality in women worldwide. The availability of prophylactic vaccines for high-risk types of human papillomavirus (HPV) infection represents an important advancement in the prevention of cervical cancer. In Jordan, the availability of the HPV vaccination is restricted to individuals who are willing to pay. The aim of the current study was to evaluate the willingness and attitude of female university students in health schools/faculties in Jordan to get HPV vaccination and their knowledge about the virus. A self-administered online questionnaire was distributed in October 2021, which comprised 27 items to evaluate HPV knowledge, history of HPV vaccination, intentions to get the HPV vaccine, and the reason(s) behind vaccine refusal for those who rejected vaccination. The study sample comprised 836 participants: medical students (39.7%), pharmacy students (26.0%), dental students (21.2%), and nursing students (13.2%). Only 524 participants had heard of HPV prior to the study (62.7%), of which 48.7% knew about the availability of HPV vaccines. The lowest level of HPV knowledge was observed among nursing students. Only 19/524 students reported a history of HPV vaccination (3.6%). The overall willingness to receive HPV vaccination if provided freely was 75.0%, while only 16.0% were willing to pay for the vaccine. The most common reason for HPV vaccine rejection was the perceived low risk to get HPV infection. Significantly higher intentions to get HPV vaccination were found among older participants and medical students. The embrace of vaccine conspiracy beliefs was associated with a significantly less willingness to get the HPV vaccination (p < 0.001). Dependence on the internet/social media as the source of HPV knowledge was associated with a significantly lower intention to get HPV vaccination (p = 0.002). The coverage of the HPV vaccination among female university students in health schools in Jordan appeared extremely low; however, three-fourths of the students who had heard of HPV were willing to receive the HPV vaccination if provided freely. Complacency appeared as a major factor for HPV vaccine rejection. Increasing the levels of knowledge and awareness of HPV infection and its association with cervical cancer through reliable sources is recommended. This can be helpful for the individual benefit of the students besides the potentially positive role they can play in community education. Countering vaccine conspiracy beliefs with proper education and awareness programs can be helpful to appraise the role of HPV vaccines in cancer prevention. Full article
(This article belongs to the Special Issue Human Papillomavirus, Vaccines and Women's Health)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop